HARP Stock Overview
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Harpoon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.01 |
| 52 Week High | US$23.21 |
| 52 Week Low | US$3.11 |
| Beta | 2.1 |
| 11 Month Change | 2.49% |
| 3 Month Change | 162.97% |
| 1 Year Change | 243.43% |
| 33 Year Change | -88.71% |
| 5 Year Change | -81.26% |
| Change since IPO | -82.96% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified
Jan 30
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough
Oct 01Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Aug 14Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically
May 28Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04Shareholder Returns
| HARP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 4.4% | 5.1% |
| 1Y | 243.4% | 30.4% | 36.3% |
Return vs Industry: HARP exceeded the US Biotechs industry which returned 16% over the past year.
Return vs Market: HARP exceeded the US Market which returned 31% over the past year.
Price Volatility
| HARP volatility | |
|---|---|
| HARP Average Weekly Movement | 32.6% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HARP's share price has been volatile over the past 3 months.
Volatility Over Time: HARP's weekly volatility has increased from 21% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 53 | Julie Eastland | www.harpoontx.com |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications.
Harpoon Therapeutics, Inc. Fundamentals Summary
| HARP fundamental statistics | |
|---|---|
| Market cap | US$492.35m |
| Earnings (TTM) | -US$30.50m |
| Revenue (TTM) | US$37.34m |
13.2x
P/S Ratio-16.1x
P/E RatioIs HARP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HARP income statement (TTM) | |
|---|---|
| Revenue | US$37.34m |
| Cost of Revenue | US$58.63m |
| Gross Profit | -US$21.29m |
| Other Expenses | US$9.21m |
| Earnings | -US$30.50m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | -57.02% |
| Net Profit Margin | -81.67% |
| Debt/Equity Ratio | 194.4% |
How did HARP perform over the long term?
See historical performance and comparison